Louis Gleckel Net Worth

The estimated Net Worth of Louis Md Gleckel is at least $739 mil dollars as of 13 August 2020. Louis Gleckel owns over 50,000 units of ProPhase Labs Inc stock worth over $739,368 and over the last 14 years he sold PRPH stock worth over $0. In addition, he makes $0 as Independent Director at ProPhase Labs Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Louis Gleckel PRPH stock SEC Form 4 insiders trading

Louis has made over 2 trades of the ProPhase Labs Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of PRPH stock worth $137,500 on 13 August 2020.

The largest trade he's ever made was buying 100,000 units of ProPhase Labs Inc stock on 26 March 2020 worth over $175,000. On average, Louis trades about 6,000 units every 6 days since 2010. As of 13 August 2020 he still owns at least 273,840 units of ProPhase Labs Inc stock.

You can see the complete history of Louis Gleckel stock trades at the bottom of the page.

Louis Gleckel biography

Dr. Louis Gleckel M.D. serves as Independent Director of the Company. He has been a member of our Board since June 2009 and currently serves as a member of our Compensation Committee and chairman of our Governance and Nominating Committee. In 1997, Dr. Gleckel co-founded ProHealth Care Associates, a comprehensive state of the art multi-specialty physician group practice with offices in Long Island and Bronx, New York. At ProHealth, he is the Division Chief of Cardiology and Internal Medicine specializing in Preventative Cardiology, Metabolic Syndrome and Internal Medicine with particular emphasis on high-risk patients with complications from diabetes and heart disease. He was named to New York Magazine’s Best Doctors list for three years, New York Metro Area Best Doctors list for 14 years and the 2008 Nassau County Best Doctors list. For over ten years Dr. Gleckel has been a team physician for the New York Jets and New York Islanders as well as for the tennis players at the US Open. Dr. Gleckel also served as Chairman of the Board of Invicta Corporation, a development stage company that designed, manufactured and marketed photochromic eyeglass lenses, for approximately four years until his resignation in February 2005.

How old is Louis Gleckel?

Louis Gleckel is 64, he's been the Independent Director of ProPhase Labs Inc since 2009. There are no older and 6 younger executives at ProPhase Labs Inc.

Insiders trading at ProPhase Labs Inc

Over the last 15 years, insiders at ProPhase Labs Inc have traded over $6,868,501 worth of ProPhase Labs Inc stock and bought 2,996,691 units worth $4,189,802 . The most active insiders traders include Braden Michael Leonard, Ted William Karkus, eJames T Mccubbin. On average, ProPhase Labs Inc executives and independent directors trade stock every 98 days with the average trade being worth of $586,896. The most recent stock trade was executed by Ted William Karkus on 1 February 2023, trading 500,000 units of PRPH stock currently worth $300,000.

What does ProPhase Labs Inc do?

prophase labs is a diversified natural health medical science company. for more information visit us at www.prophaselabs.com.

Complete history of Louis Gleckel stock trades at ProPhase Labs Inc

ProPhase Labs Inc executives and stock owners

ProPhase Labs Inc executives and other stock owners filed with the SEC include:

• Ted William Karkus,
  Chairman & CEO
• Monica Brady,
  Chief Financial Officer
• Ted Karkus,
  Chairman of the Board, Chief Executive Officer
• Monica Brady,
  Chief Financial Officer
• Warren Hirsch,
  Independent Director
• Louis Gleckel,
  Independent Director
• Jason Barr,
  Independent Director
• Sergio Miralles,
  Exec. VP & Chief Information Officer of ProPhase Diagnostics
• Sam A. Beeler,
  Chief Strategy Officer of Precision Medicine
• Jason Karkus,
  Exec. VP & Co-COO
• Alice Lioi,
  Exec. VP & Co-COO
• Mark S Leventhal,
  Director
• Mark Shawn Frank,
  Director
• James T Mccubbin,
  Director
• Mark A. Burnett,
  Director
• Braden Michael Leonard,
  10% owner
• Guy J Quigley,
  10% owner
• Robert V Jr Cuddihy,
  Chief Operating Officer
• John De Shazo,
  Director
• Jed Latkin,
  Director
• Robert A. Jr. Morse,
  CHIEF FINANCIAL OFFICER